

Suppl. Table 5. Drug concentrations that decrease the viability of V600E BRAF-mutated melanoma cells by 50% (IC₅₀).

Cell line	IC ₅₀ PLX4032 (μ M)
Colo-679	0.17 \pm 0.03
Colo-679 ^r PLX4032 ¹⁰ μ M	16.51 \pm 1.31
IGR-39	0.23 \pm 0.04
IGR-39 ^r PLX4032 ²⁰	9.94 \pm 1.51
MelHO	0.13 \pm 0.05
MelHO ^r PLX4032 ¹⁰ μ M	37.86 \pm 2.82
RVH-421	0.10 \pm 0.01
RVH-421 ^r PLX4032 ¹⁰ μ M	14.61 \pm 1.50

	PLX4720 (μ M)
Colo-679	0.26 \pm 0.07
Colo-679 ^r PLX4720 ¹⁰ μ M	30.01 \pm 1.95
IGR-39	0.41 \pm 0.06
IGR-39 ^r PLX4720 ²⁰ μ M	23.93 \pm 0.54
MelHO	0.21 \pm 0.03
MelHO ^r PLX4720 ¹⁰ μ M	24.53 \pm 7.35
RVH-421	0.05 \pm 0.04
RVH-421 ^r PLX4720 ¹⁰ μ M	37.71 \pm 4.69

	IC ₅₀ vincristine (ng/mL)
Colo-679	3.57 ± 0.38
Colo-679 ^r VCR ²⁰	80.59 ± 8.67
IGR-39	1.54 ± 0.10
IGR-39 ^r VCR ¹⁰	8.95 ± 2.23
MelHO	0.95 ± 0.09
MelHO ^r VCR ²⁰	95.77 ± 53.03

	IC ₅₀ mitoxantrone (ng/mL)
RVH-421	4.81 ± 0.53
RVH-421 ^r Mitox ¹⁰	24.97 ± 4.82
